Author

Ha Trong Khang Pham

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

#protein folding Oct 2026

PBPK Model-Based Prediction of Optimal Rosuvastatin Dosing with Concomitant Ticagrelor in Elderly Patients Considering ABCG2 Genetic Variant.

Aims Rosuvastatin is commonly co-administered with ticagrelor in patients with acute coronary syndrome. Ticagrelor inhibits breast cancer resistance protein (BCRP/ABCG2), increasing rosuvastatin exposure and potentially the risk of rhabdomyolysis. This risk may be further influenced by age and the ABCG2 c.421C>A varian...

D. H. Nguyen, H. T. V. Pham, J. Ding et al. · medRxiv · 0 citations

Open access Sep 2026

Finerenone versus spironolactone in heart failure with mildly reduced or preserved ejection fraction: a real-world study.

AIMS Finerenone has shown benefit in chronic kidney disease, type 2 diabetes, and heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), but head-to-head data against spironolactone are limited. We compared 12-month effectiveness and safety after finerenone versus spironolactone initiation in...

Ha Trong Khang Pham, Chieh-Ju Chao, Chung-Lieh Hung et al. · ESC Heart Failure · 0 citations